Clinical Trial Detail

NCT ID NCT02521051
Title Phase I/II Trial of Alectinib and Bevacizumab in Patients With Advanced, Anaplastic Lymphoma Kinase (ALK)-Positive, Non-Small Cell Lung Cancer
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements yes
Sponsors Massachusetts General Hospital
Indications

lung non-small cell carcinoma

Therapies

Bevacizumab

Alectinib

Age Groups: adult

Additional content available in CKB BOOST